Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in non-Hodgkin's lymphoma

Medical Oncology

Volumn 22, Issue 3, 2005, Pages 257-267

  Sparano, Joseph A ^a   Negassa, Abdissa ^a   Lansigan, Erick ^a   Locke, Robin ^a   De Silva, Chamath R ^a   Wiernik, Peter H ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Our Lady of Mercy Cancer Center   (United States)

Author keywords

Granulocyte macrophage colony stimulating factor; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOXEMIA; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPHIL; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SYNCOPE; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS;

EID: 23844516404     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:3:257     Document Type: Article

References (54)

1. Jemal A, et al. Cancer statistics, 2004. CA: A Journal for Cancer Clinicians 2004; 54: 8-29.
2. Harris NL, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193-207.
3. Fisher RI, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002-1006.
4. Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1997; 40 (suppl): S42-46.
5. Coiffier B, et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Pfreundschuh MG, et al. Randomized intergroup trial of first line treatment for patients < = 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proceedings of American Society of Clinical Oncology 2004; 24: 556 (abs 6500).
7. Habermann TM, et al. Phase II trial of rituximab-CHOP (R-CHOP) with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Proc Am Soc Hematol 2003 (abstr 8).
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Eng J Med 1993; 329: 987-994.
9. Lai G, et al. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991; 49: 696-703.
10. Matsushima Y, Kanzawa F, Hoshi A. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemotherap Pharamacol 1985; 14: 104-109.
11. Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989; 49: 5994-5998.
12. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-1079.
13. Wilson WH, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-1582.
14. Guiterrez M, et al. Role of doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633-3642.
15. Wilder DD, Ogden J, Jain VK. Multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2001; 1: 285-292.
16. Carrion JR, Garcia Arroyo FR, Salinas P. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 1995; 18: 44-46.
17. Case DC Jr, Aronson FR, Ervin TJ. EPOCH chemotherapy for recurrent lymphoma. Proc Am Soc Clin Oncol 1996; 15: 419 (abstr 1289).
18. Lichtman SM, et al. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. Ann Oncol 2000; 11: 1141-1146.
19. Sparano JA, Weller E, Nazeer T, Habermann TM, Traynor, A, Cassileth P. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor prognosis intermediate- or high-grade non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood 2002; 100: 1634-1640.
20. Sparano JA, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an eastern cooperative oncology group trial (E1494). J Clin Oncol 2004; 22: 1491-1500.
21. Wilson WH, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685-2693.
22. Little RF, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101: 4653-4659.
23. Chu E, DeVita VT. In: DeVita VT, Hellman S, Rosenberg S (eds). Cancer principles and practice of oncology. Lippinocott, Williams and Wilkins: Philadelphia, PA, 2001, pp. 289-306.
24. Kwak LW, et al. Prognostic significance of actual dose-intensity in diffuse large-cell lymphoma: results of a tree-structure survival analysis. J Clin Oncol 1990; 8: 963-977.
25. Lepage E, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d-Etude des Lymphomes de l'Adulte). Ann Oncol 1993; 4: 651-656.
26. Gordon LI, et al. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood 1999; 94: 3307-3314.
27. Blayney DW, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone my improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003; 21: 2466-2473.
28. Pfreundschuh M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
29. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elder patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
30. Synold TW, Doroshow JH. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96 hour continuous intravenous infusion. J Infus Chemother 1996; 2: 69-73.
31. Vadhan-Raj S, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266-1277.
32. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.
33. Fisher, RI, et al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 45-51.
34. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684-692.
35. Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
36. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
37. Suissa S, Shuster J. The 2x2 matched-pair trial: exact unconditional design and analysis. Biometrics 1991; 47: 361-372.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
39. Fleming TR, Harrington DP. A class of hypothesis tests for one and two samples of censored survival data. Communi Stat 1981; 10: 763-794.
40. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 63-170.
41. Sparano JA (ed). Cancer treatment and research: HIV- and HTLV-I associated malignancies. Kluwer Academic Publishers? Norwell, MA, 2001.
42. Sparano JA, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: a highly active regimen. Blood 1993; 81: 2810-2815.
43. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122: 413-423.
44. Bennett CL, et al., for the Health Services Research Committee of the American Society of Clinical Oncology Use of Hematopoietic Colony-Stimulating Factors. Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys regarding ASCO clinical practice guidelines. J Clin Oncol 1999; 17: 3676-3681.
45. Kobrinsky NL, Sjolander DE, Cheng MS, Levit R, Steen PD. Granulcoyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early stage breast cancer. J Clin Oncol 1999; 17: 3426-3430.
46. Aglietta M, et al. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin's disease. Cancer 2000; 88: 454-460.
47. Jani JE, et al. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan induced neutropenia in chemotherapy-naïve patients with malignant melanoma and renal cell carcinoma. Blood 2001; 97: 1942-1946.
48. Aglietta M, et al. Kinetics of human hemapoiteic cells after in vivo administration of granulocyte-macrophage colony simulating factor. J Clin Inves 1999; 83: 551-557.
49. Vivianne CG, et al. Enhanced myelotoxicity due to granulocyte colony stimulating factor administration until 48 hours before the next chemotherapy course in patients with small cell lung cancer. J Clin Oncol 1998; 16: 2708-2714.
50. Holmes FA, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjuvant to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
51. Vose JM, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
52. Green MK, et al. A randomized double-blind multicenter phase III study of fixed-dose singe-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
53. Demiden A, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
54. Maloney DG, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.